3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
157
Carcinoma, Intraductal, Noninfiltrating
16
Breast Carcinoma In Situ
12
Neoplasm Metastasis
9
Ovarian Neoplasms
7
Breast Neoplasms, Male
7
Neoplasms
4
Prostatic Neoplasms
3
Inflammatory Breast Neoplasms
3
Glioblastoma
3
Breast Cancer Female
3
Urinary Bladder Neoplasms
2
Recurrence
2
Pancreatic Neoplasms
2
Obesity
2
Infertility
2
Hot Flashes
2
Fibroadenoma
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
ER+ Breast Cancer
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Sleep Wake Disorders
1
Sexuality
1
Risk Reduction Behavior
1
Rhabdoid Tumor
1
Pyloric Stenosis, Hypertrophic
1
Primary Breast Cancer
1
Interventions
testosterone undecanoate
3
Testosterone
3
testosterone 17 beta-cypionate
1
Triptorelin Pamoate
1
Testosterone Propionate
1
Tamoxifen
1
Surveys and Questionnaires
1
Standard of Care
1
Specimen Handling
1
Practice Guidelines as Topic
1
Orchiectomy
1
Observation
1
Methyltestosterone
1
Mental Status and Dementia Tests
1
Gonadotropin-Releasing Hormone
1
Gels
1
Drug Evaluation
1
Clomiphene
1
Castor Oil
1
Blood Specimen Collection
1
Anastrozole
1
Alendronate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hypogonadism
×
Tamoxifen
×
Clear all
NCT07535905
2026-04-17
REVIVE
University Health Network, Toronto
Phase 2
Not yet recruiting
96 enrolled